Latest Conference Articles

April 26th 2016, 7:46am

School of Gastrointestinal Oncology

Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

April 26th 2016, 6:53am

School of Gastrointestinal Oncology

Michael Choti, MD, explains the impact of advancements in the treatment of patients with liver cancer and how building on them will require all oncology professionals to work as a team.

April 23rd 2016, 11:43am

School of Gastrointestinal Oncology

Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.

April 23rd 2016, 11:06am

School of Gastrointestinal Oncology

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.

April 23rd 2016, 9:28am

School of Gastrointestinal Oncology

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

April 23rd 2016, 8:05am

School of Gastrointestinal Oncology

John L. Marshall, MD, discusses how the management of patients with gastrointestinal cancers requires a multidisciplinary approach.

April 23rd 2016, 6:11am

School of Gastrointestinal Oncology

Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors.

April 20th 2016, 4:30pm

AACR Annual Meeting

More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.

April 20th 2016, 8:47am

AACR Annual Meeting

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

April 19th 2016, 2:58pm

AACR Annual Meeting

Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.

April 19th 2016, 1:54pm

AACR Annual Meeting

The addition of three biological markers to conventional breast cancer risk models significantly improved the ability to distinguish women at high and low risk.

April 19th 2016, 12:02pm

AACR Annual Meeting

Anti–PD-1 therapy in the first-line induced responses in more than half of patients with advanced Merkel cell carcinoma, with encouraging durability to the responses.

April 19th 2016, 10:00am

AACR Annual Meeting

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).

April 19th 2016, 8:00am

AACR Annual Meeting

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).

April 19th 2016, 7:32am

AACR Annual Meeting

Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

April 19th 2016, 6:55am

European Lung Cancer Congress

Fred R. Hirsch, MD, PhD, professor of medicine and pathology, University of Colorado Cancer Center, CEO, International Association for the Study of Lung Cancer (IASLC), discusses necitumumab for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC).

April 19th 2016, 6:08am

AACR Annual Meeting

Three currently available assays for PD-L1 expression exhibited a high degree of correlation in a comparative study involving archived lung cancer tissue.

April 18th 2016, 2:42pm

AACR Annual Meeting

The combination of ado-trastuzumab emtansine and pertuzumab was superior to the combination of paclitaxel and trastuzumab as neoadjuvant treatment for women with HER2-positive breast cancer.

April 18th 2016, 2:30pm

AACR Annual Meeting

The combination of the PARP inhibitor olaparib and the investigational AKT inhibitor AZD5363 resulted in durable responses in patients with solid tumors, with and without BRCA mutations.

April 18th 2016, 1:46pm

AACR Annual Meeting

Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood